| Primary information |
|---|
| sequence ID | Seq_4220 |
| Peptide sequence | KITHRIHWESASLL |
| CancerPDF_ID | CancerPDF_ID29, CancerPDF_ID195, CancerPDF_ID208, CancerPDF_ID1045, CancerPDF_ID8547, CancerPDF_ID12705, |
| PMID | 16896061,19728888,19728888,16395409,23667664,27058005 |
| Protein Name | Complement C3f,Complement C3f,Complement C3 f,Complement C3f,Complement C3f,Complement C3 |
| UniprotKB Entry Name | CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN |
| Fluid | Serum,Serum,Serum,Serum,Serum,Serum |
| M/Z | 1690.9,1690.9254,1690.9254,1690.9,1689.93,1690.987 |
| Charge | 1,NA,NA,1,1,NA |
| Mass (in Da) | 1690.93,NA,NA,NA,1691.97,NA |
| fdr | NA,NA,NA,NA,NA,NA |
| Profiling Technique | MALDI-TOF,MALDI-TOF,MALDI-TOF,MALDI-TOF,MALDI-TOF,MALDI-TOF |
| Peptide Identification technique | Q/TOF MS/MS,LC-MS/MS,LC-MS/MS,Q/TOF/TOF and LC-MS/MS,FT-ICR MS/MS + nano-HPLC,LC-MS/MS |
| Quantification Technique | NA,NA,NA,NA,NA,NA |
| Labelled/Label Free | Label Free,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | NA,NA,NA,less than 1 “5,NA,NA |
| CancerPDF_ID | CancerPDF_ID29, CancerPDF_ID195, CancerPDF_ID208, CancerPDF_ID1045, CancerPDF_ID8547, CancerPDF_ID12705, |
| p-Value | 1.00E-05,less than 0.05,2.83E-05,4.77E-13,NA,"less than 0.001,less than 0.05,0.096" |
| Software | MASCOT,MASCOT(v 2.0.04 for Windows),MASCOT(v 2.0.04 for Windows),MASCOT (v 2.0.04 for Windows),MASCOT,Proteome Discoverer |
| Length | 14,14,14,14,14,14 |
| Cancer Type | Metastatic thyroid carcinomas,"Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy","Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy","Advanced Prostate, Breast and Bladder cancer","Breast cancer, Lung cancer, Rectal cancer",Breast cancer |
| Database | NCBI refseq Protein Database,SwissProt Database (release 54.7),SwissProt Database (release 54.7),NCBI refseq Protein Database,NA,SwissProt Database |
| Modification | NA,NA,NA,NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"11 NSCLC patients with the shortest PFS, 11 patients with the longest PFS","27 patients, 13 normal individuals","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy","Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy"," 28 were diagnosed with Breast cancer, 27 remained cancer-free with BRCA carrier. Of the remaining patients, 39 were diagnosed with sporadic breast cancer (SBC), and 38 were healthy volunteers (WT)." |
| Regulation | Differentially expressed between cancer vs normal samples,Peptide Ion Signature for differentiation between Short PFS(Progression Free survival) versus long PFS,Differentially expressed between NSCLC patients vs healthy volunteers,"For Prostate & bladder (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =4.05, 6.85 and 1.01 in prostate, bladder and breast cancer respectively",NA,"Upregulated with the fold change of 2.19 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.36, Upregulated in BC vs healthy with 1.341 fold change" |
| Validation | Independent validation,Independent validation,Independent validation,Independent validation,NA,NA |
| Sensitivity | 95% on independent dataset,1,1,97.5% for multiclass and 100 % for binary classification system on independent validation dataset,NA,NA |
| Specificity | 95% on independent dataset,0.73,0.96,NA,NA,NA |
| Accuracy | NA,0.86,0.98,97.5 % on validation dataset,NA,NA |
| Peptide Atlas | NA |
| IEDB | 533899
|